Overview of the launch progress of Tucatinib in China

Tucatinib (Tucatinib), as an innovative targeted drug specially designed for HER2 positive breast cancer patients, was carefully developed by the well-known American biopharmaceutical company Seattle Genetics (now owned by Seagen). In December 2019, the drug was approved by the U.S. Food and Drug Administration (FDA), becoming a new hope for the treatment of advanced or metastatic HER2-positive breast cancer, especially for patients who have gone through multiple treatment options. Its excellent performance and safety in clinical studies have been widely recognized.

Although tucatinib (tucatinib) has made remarkable achievements globally, unfortunately, it has not yet been officially launched in the Chinese market. However, the outstanding performance and good reputation of this innovative drug internationally have made domestic breast cancer patients and the medical community full of expectations for it, viewing it as a potentially important new treatment option. Currently, if domestic patients want to use tucatinib, they still need to purchase it through overseas channels. In foreign markets, there are both original drugs and generic drugs to choose from. Among them, original drugs are mainly European versions and are expensive, reaching tens of thousands of yuan; while generic drugs are mainly from Laos and Bangladesh and are relatively affordable, about three to four thousand yuan, and their drug ingredients are basically the same as the original drugs.

Clinical trials worldwide have further confirmed the excellent efficacy of tucatinib . TucatinibHerceptin) and capecitabine (Capecitabine) >Can significantly prolong the progression-free survival (PFS) and overall survival (OS) of patients with HER2 positive breast cancer. Especially in the pivotal HER2CLIMB trial, patients who received tucatinib (tucatinib) combination therapy showed a clear survival advantage compared to the control group. These positive data undoubtedly provide strong support for the future approval and application of tucatinib in China.

In addition to its remarkable efficacy, tucatinib also has excellent safety and tolerability. Although patients may experience common adverse effects such as diarrhea, hand-foot syndrome, nausea, and fatigue, most patients can effectively manage these side effects through adjustment of drug dosage and symptomatic treatment. This enables tucatinib to demonstrate good operability and patient compliance during treatment, further enhancing its clinical application value.